Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-30,000
Closed -$3.29M 5121
2023
Q4
$3.29M Buy
+30,000
New +$3.1M ﹤0.01% 2484
2023
Q1
Sell
-170,000
Closed -$15.1M 5127
2022
Q4
$15.1M Hold
170,000
0.01% 1017
2022
Q3
$13.6M Buy
+170,000
New +$16M 0.01% 741
2022
Q1
Sell
-107,400
Closed -$15.2M 5030
2021
Q4
$15.2M Buy
+107,400
New +$15.2M 0.01% 1058

Other funds holding CNMD

Barclays's CNMD Position: Q1 2026 in Review

Barclays reduced its CONMED (CNMD) stake by 73% in Q1 2026, selling an estimated $3.56M and leaving 32,730 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2671.

Barclays first reported a position in CNMD in Q2 2013 and has held it in 50 quarters since. The position peaked at $49.6M in Q2 2023. 236 funds tracked by Wall St. Rank hold CNMD as of Q1 2026.

  • Barclays held 32,730 shares of CONMED worth $1.16M as of Q1 2026.
  • Barclays sold 87,475 CONMED shares in Q1 2026, an estimated $3.56M.
  • CONMED made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2671 holding.
  • Barclays first reported a position in CONMED in Q2 2013 and has held it in 50 quarters since.
  • Barclays's CONMED position peaked at $49.6M in Q2 2023.
  • 236 funds tracked by Wall St. Rank held CONMED as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.